A Phase 1/2 interventional study of Sym015 in Oncology, MET Gene Amplification and NSCLC, sponsored by Symphogen A/S. Completed at 27 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-22.
Sponsored by Symphogen A/S · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 895 under way, 141 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.
Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,485th largest by enrollment of the 3,001 interventional ones that give a count, is one of 137 that started in 2016, is one of 487 in phase 1/2, and was the 1,676th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →521 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Indiana University · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1,415 · Phase 2 1,596 · Phase 3 382 · Phase 4 13
First in 1990; this study’s year is marked. 137 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is close to the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 56 across the 3,001 interventional studies, 100 across the 246 observational. Of the 2,302 that completed or were terminated, 1,054 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,741 of 3,374 have an industry lead sponsor. The 10 most frequent:
Symphogen A/S is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.
Symphogen A/S has 2 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
267 of the studies in Carcinoma, Non-Small-Cell Lung with a site in United States that are under way reach primary completion within a year, 24 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT03637816Phase 3M.D. Anderson Cancer CenterAnamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | 2026-12-31 |
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
Add all 267 to your calendar (.ics) → With an account.
Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is the first study to test Sym015 in humans. The primary purpose of this study is to see if Sym015 is safe and effective for patients with advanced solid tumor malignancies without available therapeutic options.
In the first part of the study (Part 1, dose-escalation), Sym015 was evaluated for safety and tolerability. Additionally, the recommended Phase 2 dose (RP2D) was to be determined. Sym015 was given at different dose levels on an every second week (Q2W) dosing schedule. Each patient was given one single weight based dose level.
In the second part of the study (Part 2, dose-expansion), dosing was to be at the RP2D on a Q2W dosing schedule. Three cohorts were included:
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
This study's enrollment of 57 is close to the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Symphogen A/S is the lead sponsor of 16 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.
Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 2 ONLY:
Basket Cohort ONLY:
NSCLC MET-Amplified Cohort ONLY:
NSCLC METex14del Cohort ONLY:
Exclusion Criteria:
Part 2 ONLY:
Basket Cohort ONLY:
Basket Cohort and NSCLC MET-Amplified Cohort ONLY:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sym015 was tested in four dose titration cohorts. Patients in this cohort received 6 mg/kg. A substitute or an additional dose level could potentially be evaluated.
Drug: Sym015
Sym015 was tested in four dose titration cohorts. Patients in this cohort received 12 mg/kg. A substitute or an additional dose level could potentially be evaluated.
Drug: Sym015
Sym015 was tested in four dose titration cohorts. Patients in this cohort received 18 mg/kg. A substitute or an additional dose level could potentially be evaluated.
Drug: Sym015
Sym015 was tested in four dose titration cohorts. Patients in this cohort received 24 mg/kg. A substitute or an additional dose level could potentially be evaluated.
Drug: Sym015
Patients with KRAS WT advanced solid tumor malignancies with MET-amplification were to receive Sym015 at the RP2D. Included in this group was a subset of patients who have received prior therapy with a MET-targeting TKI.
Drug: Sym015
Patients with advanced NSCLC with MET-amplification were to receive Sym015 at the RP2D. Patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents.
Drug: Sym015
Patients with advanced NSCLC with METex14del were to receive Sym015 at the RP2D. Tumors need not be MET-amplified, and patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents. mutation.
Drug: Sym015
Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.
Also known as: Anti-MET
Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration
The primary objective of Part 1 was to assess the safety and tolerability of Sym015 on a Q2W schedule. This was assessed by evaluating the occurrence of dose-limiting toxicities (DLTs) during Cycle 1 of Sym015 administration. Q2W = every second week.
Time frame: Cycle 1, the initial 28-day period of Q2W dosing
Part 2: Documented, Confirmed Objective Response (OR)
The primary objective of Part 2 was to evaluate the antitumor activity of Sym015 when administered at the Q2W RP2D to patients in the different cohorts. Documented OR was defined as partial response \[PR\] or complete response \[CR\]) as assessed by CT or MRI using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; CR = Disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). Q2W = every second week. RP2D = recommended phase 2 dose.
Time frame: 24 months
Part 1: Determine a Q2W RP2D of Sym015.
Determination based on an evaluation of the patient data for DLTs from Part 1. Q2W = every second week. RP2D = recommended phase 2 dose.
Time frame: 12 Months
Immunogenicity of Sym015: Part 1.
Serum sampling was done to assess the potential for anti-drug antibody (ADA) formation.
Time frame: Cycle 1: Day (D) 1, Cycle 3, 5, 7: D1 (+-2), End of treatment: At or by D10, Follow-up: 1 month after last dose of study treatment (30+7D)
Immunogenicity of Sym015: Part 2.
Serum sampling was done to assess the potential for anti-drug antibody (ADA) formation.
Time frame: Cycle 1: Day (D) 1, Cycle 2, 3, 5, 7: D1 (+-2), End of treatment: At or by D10, Follow-up: 1 month after last dose of study treatment (30+7D)
Part 1: Area Under the Concentration-time Curve in a Dosing Interval (AUC) Following 1st Dose
Estimated using non-compartmental methods and actual time points following the first dose of Sym015.
Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Part 2: Area Under the Concentration-time Curve in a Dosing Interval (AUC)
Estimated using non-compartmental methods and actual time points following the first dose of Sym015 for the whole basket cohort.
Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Part 1: Cmax
Maximum serum concentration was derived from observed data.
Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Part 2: Cmax
Maximum serum concentration was derived from observed data following the first dose of Sym015 for the full basket cohort.
Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Part 1: Time to Reach Maximum Concentration (Tmax)
Time to reach maximum concentration (Tmax) was derived from observed data.
Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Part 2: Time to Reach Maximum Concentration (Tmax)
Time to reach maximum concentration (Tmax) was derived from observed data following the first dose of Sym015 for the full basket cohort.
Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Part 1: Trough Concentration (Ctrough)
Ctrough was derived from observed data.
Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Part 2: Trough Concentration (Ctrough)
Ctrough was derived from observed data following the first dose of Sym015 for the whole basket cohort.
Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Part 1: Elimination Half-life (T½)
Estimated using non-compartmental methods and actual time points.
Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Part 2: Elimination Half-life (T½)
Estimated using non-compartmental methods and actual time points following the first dose of Sym015 for the whole basket cohort.
Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Part 1: Clearance (CL)
Estimated using non-compartmental methods and actual time points.
Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Part 2: Clearance (CL)
Estimated using non-compartmental methods and actual time points following the first dose of Sym015 for the whole basket cohort.
Time frame: From time zero to 48 hours after dosing. Samples taken pre-dosing and at 1, 2, 4, 8, 24 and 48 hours after end of infusion.
Part 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by OR.
This applies to the subset of patients in the Basket Cohort who received prior therapy with a MET-targeting TKI. Documented OR (defined as PR or CR), assessed by RECIST v1.1 at any time during trial participation by Investigator assessment. Objective Response (OR) is presented. Documented OR was defined as partial response \[PR\] or complete response \[CR\]) as assessed by CT or MRI using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; CR = Disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis).
Time frame: 24 Months
Part 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by DCR.
This applies to the subset of patients in the Basket Cohort who received prior therapy with a MET-targeting TKI. Documented OR (defined as PR or CR), assessed by RECIST v1.1 at any time during trial participation by Investigator assessment. Disease control rate (DCR) is presented. The DCR was defined as the percentage of patients who had BOR of confirmed CR or confirmed PR or SD (including unconfirmed CR/PR, provided 6 weeks minimum criteria for SD duration was met). BOR = Best Overall Response. CR = Complete Response. PR = Partial Response. SD = Stable Disease.
Time frame: 24 Months
| Milestone | Part 1: Dose-Escalation; Period 1: 6 mg/kg | Part 1: Dose-Escalation; Period 2: 12mg/kg | Part 1: Dose-Escalation; Period 3:18mg/kg | Part 1: Dose-Escalation; Period 4: 24 mg/kg | Part 2: Dose-Expansion, Basket Cohort | Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort | Part 2: Dose-Expansion, NSCLC METEx14Del Cohort |
|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 25 | 8 | 12 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 3 | 3 | 25 | 8 | 12 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 2 | 2 | 2 | 3 | 22 | 7 | 8 |
| Withdrew: Other reason (unknown) | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Transferred to named patient program | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
The primary objective of Part 1 was to assess the safety and tolerability of Sym015 on a Q2W schedule. This was assessed by evaluating the occurrence of dose-limiting toxicities (DLTs) during Cycle 1 of Sym015 administration. Q2W = every second week.
| Number of DLTs | Part 1: Dose-Escalation; Period 1, 6 mg/kg | Part 1: Dose-Escalation; Period 2: 12mg/kg | Part 1: Dose-Escalation; Period 3:18mg/kg | Part 1: Dose-Escalation; Period 4: 24 mg/kg |
|---|---|---|---|---|
| Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration | 0 | 0 | 0 | 0 |
The primary objective of Part 2 was to evaluate the antitumor activity of Sym015 when administered at the Q2W RP2D to patients in the different cohorts. Documented OR was defined as partial response \[PR\] or complete response \[CR\]) as assessed by CT or MRI using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; CR = Disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). Q2W = every second week. RP2D = recommended phase 2 dose.
| Participants | Part 2: Basket Cohort | Part 2: Patients in NSCLC MET-Amplified Cohort | Part 2: Patients in NSCLC METEx14Del Cohort |
|---|---|---|---|
| Part 2: Documented, Confirmed Objective Response (OR) | 0 | 2 | 3 |
Determination based on an evaluation of the patient data for DLTs from Part 1. Q2W = every second week. RP2D = recommended phase 2 dose.
| mg/kg | Part 1: Dose-Escalation (4 Arms Combined) |
|---|---|
| Part 1: Determine a Q2W RP2D of Sym015. | NA |
Serum sampling was done to assess the potential for anti-drug antibody (ADA) formation.
| Participants | 6 mg/kg | 12 mg/kg | 18 mg/kg | 24 mg/kg |
|---|---|---|---|---|
| Cycle 1 - day 1 — Not done | 0 | 0 | 0 | 0 |
| Cycle 1 - day 1 — Negative | 3 | 3 | 3 | 3 |
| Cycle 1 - day 1 — Patient withdrawn | 0 | 0 | 0 | 0 |
| Cycle 3 - day 1 — Not done | 0 | 0 | 0 | 0 |
| Cycle 3 - day 1 — Negative | 1 | 0 | 2 | 0 |
| Cycle 3 - day 1 — Patient withdrawn | 2 | 3 | 1 | 3 |
| End of treatment — Not done | 0 | 0 | 0 | 1 |
| End of treatment — Negative | 3 | 2 | 1 | 2 |
| End of treatment — Patient withdrawn | 0 | 1 | 2 | 0 |
| 1-month follow-up — Not done | 0 | 1 | 0 | 0 |
| 1-month follow-up — Negative | 2 | 1 | 0 | 2 |
| 1-month follow-up — Patient withdrawn | 1 | 1 | 3 | 1 |
Serum sampling was done to assess the potential for anti-drug antibody (ADA) formation.
| Participants | Part 2: Basket Cohort | Part 2: Patients in NSCLC MET-Amplified Cohort | Part 2: Patients in NSCLC METEx14Del Cohort |
|---|---|---|---|
| Cycle 1 - day 1 — Not done | 0 | 0 | 0 |
| Cycle 1 - day 1 — Negative | 25 | 8 | 12 |
| Cycle 1 - day 1 — Positive | 0 | 0 | 0 |
| Cycle 1 - day 1 — Patient withdrawn | 0 | 0 | 0 |
| Cycle 2 - day 1 — Not done | 1 | 0 | 0 |
| Cycle 2 - day 1 — Negative | 21 | 8 | 11 |
| Cycle 2 - day 1 — Positive | 0 | 0 | 0 |
| Cycle 2 - day 1 — Patient withdrawn | 3 | 0 | 1 |
| Cycle 3 - day 1 — Not done | 1 | 1 | 0 |
| Cycle 3 - day 1 — Negative | 8 | 7 | 8 |
| Cycle 3 - day 1 — Positive | 0 | 0 | 0 |
| Cycle 3 - day 1 — Patient withdrawn | 16 | 0 | 4 |
| Cycle 5 - day 1 — Not done | 0 | 0 | 1 |
| Cycle 5 - day 1 — Negative | 6 | 6 | 5 |
| Cycle 5 - day 1 — Positive | 0 | 0 | 0 |
| Cycle 5 - day 1 — Patient withdrawn | 19 | 2 | 6 |
| Cycle 7 - day 1 — Not done | 0 | 1 | 0 |
| Cycle 7 - day 1 — Negative | 2 | 2 | 5 |
| Cycle 7 - day 1 — Positive | 0 | 0 | 0 |
| Cycle 7 - day 1 — Patient withdrawn | 23 | 5 | 7 |
| End of treatment — Not done | 5 | 0 | 0 |
| End of treatment — Negative | 15 | 7 | 9 |
| End of treatment — Positive | 1 | 0 | 0 |
| End of treatment — Patient withdrawn | 4 | 1 | 3 |
| 1-month follow up — Not done | 0 | 1 | 1 |
| 1-month follow up — Negative | 10 | 3 | 5 |
| 1-month follow up — Positive | 1 | 0 | 0 |
| 1-month follow up — Patient withdrawn | 14 | 4 | 6 |
Estimated using non-compartmental methods and actual time points following the first dose of Sym015.
| h*μg/mL | 6 mg/kg | 12 mg/kg | 18 mg/kg | 24 mg/kg |
|---|---|---|---|---|
| Part 1: Area Under the Concentration-time Curve in a Dosing Interval (AUC) Following 1st Dose | 17900 (17100 to 24500) | 35700 (31600 to 42900) | 82500 (75200 to 86200) | 76800 (55200 to 86400) |
Estimated using non-compartmental methods and actual time points following the first dose of Sym015 for the whole basket cohort.
| h*ug/mL | Part 2 (Dose Expansion): Basket Cohort | Part 2 (Dose Expansion): Patients in NSCLC MET-Amplified Cohort | Part 2 (Dose Expansion): Patients in NSCLC METEx14Del Cohort |
|---|---|---|---|
| Part 2: Area Under the Concentration-time Curve in a Dosing Interval (AUC) | 34000 (17300 to 51800) | 37200 (22000 to 55000) | 38700 (11300 to 54000) |
Maximum serum concentration was derived from observed data.
| ug/mL | 6 mg/kg | 12 mg/kg | 18 mg/kg | 24 mg/kg |
|---|---|---|---|---|
| Part 1: Cmax | 146 (141 to 151) | 286 (275 to 323) | 563 (419 to 711) | 561 (379 to 726) |
Maximum serum concentration was derived from observed data following the first dose of Sym015 for the full basket cohort.
| ug/mL | Part 2 (Dose-Expansion): Basket Cohort | Part 2 (Dose-Expansion): Patients in NSCLC MET-Amplified Cohort | Part 2 (Dose-Expansion): Patients in NSCLC METEx14Del Cohort |
|---|---|---|---|
| Part 2: Cmax | 420 (310 to 700) | 520 (320 to 610) | 510 (330 to 1180) |
Time to reach maximum concentration (Tmax) was derived from observed data.
| hours | 6 mg/kg | 12 mg/kg | 18 mg/kg | 24 mg/kg |
|---|---|---|---|---|
| Part 1: Time to Reach Maximum Concentration (Tmax) | 2.1 (2 to 5) | 1.1 (1 to 2) | 3.5 (3 to 4) | 3.0 (3 to 9) |
Time to reach maximum concentration (Tmax) was derived from observed data following the first dose of Sym015 for the full basket cohort.
| hours | Part 2 (Dose-Expansion): Basket Cohort | Part 2 (Dose-Expansion): Patients in NSCLC MET-Amplified Cohort | Part 2 (Dose-Expansion): Patients in NSCLC METEx14Del Cohort |
|---|---|---|---|
| Part 2: Time to Reach Maximum Concentration (Tmax) | 2.5 (1 to 44) | 3.7 (2 to 8) | 2.8 (2 to 7) |
Ctrough was derived from observed data.
| μg/mL | 6 mg/kg | 12 mg/kg | 18 mg/kg | 24 mg/kg |
|---|---|---|---|---|
| Part 1: Trough Concentration (Ctrough) | 23.1 (19.2 to 31.5) | 61.3 (56.1 to 65) | 130 (127 to 187) | 92.4 (91.3 to 151) |
Ctrough was derived from observed data following the first dose of Sym015 for the whole basket cohort.
| μg/mL | Part 2 (Dose-Expansion): Basket Cohort | Part 2 (Dose-Expansion): Patients in NSCLC MET-Amplified Cohort | Part 2 (Dose-Expansion): Patients in NSCLC METEx14Del Cohort |
|---|---|---|---|
| Part 2: Trough Concentration (Ctrough) | 84.1 (24 to 429) | 90.1 (51 to 183) | 101.7 (66 to 250) |
Estimated using non-compartmental methods and actual time points.
| hours | 6 mg/kg | 12 mg/kg | 18 mg/kg | 24 mg/kg |
|---|---|---|---|---|
| Part 1: Elimination Half-life (T½) | 179 (116 to 179) | 137 (137 to 137) | 193 (193 to 193) | 170 (170 to 170) |
Estimated using non-compartmental methods and actual time points following the first dose of Sym015 for the whole basket cohort.
| hours | Part 2 (Dose-Expansion): Basket Cohort | Part 2 (Dose-Expansion): Patients in NSCLC MET-Amplified Cohort | Part 2 (Dose-Expansion): Patients in NSCLC METEx14Del Cohort |
|---|---|---|---|
| Part 2: Elimination Half-life (T½) | 150 (87 to 217) | 191 (103 to 208) | 171 (116 to 204) |
Estimated using non-compartmental methods and actual time points.
| mL/h | 6 mg/kg | 12 mg/kg | 18 mg/kg | 24 mg/kg |
|---|---|---|---|---|
| Part 1: Clearance (CL) | 0.3 (0.3 to 0.3) | 0.2 (0.2 to 0.2) | — | — |
Estimated using non-compartmental methods and actual time points following the first dose of Sym015 for the whole basket cohort.
| mL/h/kg | Part 2 (Dose-Expansion): Basket Cohort | Part 2 (Dose-Expansion): Patients in NSCLC MET-Amplified Cohort | Part 2 (Dose-Expansion): Patients in NSCLC METEx14Del Cohort |
|---|---|---|---|
| Part 2: Clearance (CL) | 0.4 (0.2 to 0.5) | 0.2 (0.2 to 0.2) | 0.2 (0.2 to 0.2) |
This applies to the subset of patients in the Basket Cohort who received prior therapy with a MET-targeting TKI. Documented OR (defined as PR or CR), assessed by RECIST v1.1 at any time during trial participation by Investigator assessment. Objective Response (OR) is presented. Documented OR was defined as partial response \[PR\] or complete response \[CR\]) as assessed by CT or MRI using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at any time during trial participation by Investigator assessment. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; CR = Disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis).
| Participants | Patients With Prior MET-targeting TKI Therapy (Basket Cohort) | Patients Without Prior MET-targeting TKI Therapy (Basket Cohort) |
|---|---|---|
| Part 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by OR. | 0 | 0 |
This applies to the subset of patients in the Basket Cohort who received prior therapy with a MET-targeting TKI. Documented OR (defined as PR or CR), assessed by RECIST v1.1 at any time during trial participation by Investigator assessment. Disease control rate (DCR) is presented. The DCR was defined as the percentage of patients who had BOR of confirmed CR or confirmed PR or SD (including unconfirmed CR/PR, provided 6 weeks minimum criteria for SD duration was met). BOR = Best Overall Response. CR = Complete Response. PR = Partial Response. SD = Stable Disease.
| Participants | Patients With Prior MET-targeting TKI Therapy (Basket Cohort) | Patients Without Prior MET-targeting TKI Therapy (Basket Cohort) |
|---|---|---|
| Part 2: Additional Preliminary Evaluation of the Antitumor Activity of Sym015 When Administered at the Q2W RP2D in a Subset of Patients. Assessed by DCR. | 2 | 8 |
Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Dose-Escalation; Period 1: 6 mg/kg | 0/3 (0%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Part 1: Dose-Escalation; Period 2: 12mg/kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 1: Dose-Escalation; Period 3:18mg/kg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part 1: Dose-Escalation; Period 4: 24 mg/kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part 2: Dose-Expansion, Basket Cohort | 0/25 (0%) | 8/25 (32%) | 23/25 (92%) |
| Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort | 0/8 (0%) | 4/8 (50%) | 8/8 (100%) |
| Part 2: Dose-Expansion, NSCLC METEx14Del Cohort | 3/12 (25%) | 6/12 (50%) | 12/12 (100%) |
| Event | Part 1: Dose-Escalation; Period 1: 6 mg/kg | Part 1: Dose-Escalation; Period 2: 12mg/kg | Part 1: Dose-Escalation; Period 3:18mg/kg | Part 1: Dose-Escalation; Period 4: 24 mg/kg | Part 2: Dose-Expansion, Basket Cohort | Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort | Part 2: Dose-Expansion, NSCLC METEx14Del Cohort |
|---|---|---|---|---|---|---|---|
| Pelvic abscessInfections and infestations | 1/3 | 0/3 | 0/3 | 0/3 | 0/25 | 0/8 | 0/12 |
| Intra-abdominal fluid collectionGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 1/3 | 0/25 | 0/8 | 0/12 |
| NauseaGastrointestinal disorders | 0/3 | 1/3 | 0/3 | 0/3 | 0/25 | 0/8 | 0/12 |
| BacteraemiaInfections and infestations | 0/3 | 0/3 | 0/3 | 1/3 | 0/25 | 0/8 | 0/12 |
| PneumoniaInfections and infestations | 0/3 | 0/3 | 0/3 | 0/3 | 0/25 | 1/8 | 1/12 |
| InfectionInfections and infestations | 0/3 | 0/3 | 0/3 | 0/3 | 0/25 | 1/8 | 0/12 |
| Septic shockInfections and infestations | 0/3 | 0/3 | 0/3 | 0/3 | 0/25 | 1/8 | 0/12 |
| Edema peripheralGeneral disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/25 | 1/8 | 0/12 |
| HepatitisHepatobiliary disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/25 | 1/8 | 0/12 |
| Peripheral ischemiaVascular disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/25 | 1/8 | 0/12 |
| Event | Part 1: Dose-Escalation; Period 1: 6 mg/kg | Part 1: Dose-Escalation; Period 2: 12mg/kg | Part 1: Dose-Escalation; Period 3:18mg/kg | Part 1: Dose-Escalation; Period 4: 24 mg/kg | Part 2: Dose-Expansion, Basket Cohort | Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort | Part 2: Dose-Expansion, NSCLC METEx14Del Cohort |
|---|---|---|---|---|---|---|---|
| HypokalemiaMetabolism and nutrition disorders | 2/3 | 0/3 | 1/3 | 0/3 | 2/25 | 0/8 | 0/12 |
| Ear painEar and labyrinth disorders | 0/3 | 2/3 | 0/3 | 1/3 | 0/25 | 0/8 | 0/12 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/3 | 0/3 | 2/3 | 0/3 | 0/25 | 0/8 | 0/12 |
| Edema peripheralGeneral disorders | 1/3 | 1/3 | 0/3 | 0/3 | 1/25 | 3/8 | 7/12 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/3 | 1/3 | 0/3 | 0/3 | 2/25 | 1/8 | 5/12 |
| Aspartate aminotransferase increasedInvestigations | 0/3 | 0/3 | 0/3 | 0/3 | 1/25 | 3/8 | 1/12 |
| HeadacheNervous system disorders | 0/3 | 0/3 | 1/3 | 0/3 | 0/25 | 3/8 | 0/12 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/3 | 0/3 | 3/25 | 3/8 | 0/12 |
| NauseaGastrointestinal disorders | 1/3 | 0/3 | 0/3 | 0/3 | 6/25 | 2/8 | 2/12 |
| ConstipationGastrointestinal disorders | 0/3 | 1/3 | 0/3 | 1/3 | 5/25 | 2/8 | 2/12 |
| Age, Continuous(years) | Part 1: Dose-Escalation, 6 mg/kg | Part 1: Dose-Escalation, 12 mg/kg | Part 1: Dose-Escalation 18 mg/kg | Part 1: Dose-Escalation 24 mg/kg | Part 2: Dose-Expansion, Basket Cohort | Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort | Part 2: Dose-Expansion, NSCLC METex14del Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 55.7 ± 14.57 | 62.0 ± 11.79 | 55.3 ± 11.24 | 67.3 ± 7.23 | 56.6 ± 11.87 | 65.6 ± 8.91 | 68.5 ± 9.82 | 61.1 ± 11.73 |
| Age, Customized(Participants) | Part 1: Dose-Escalation, 6 mg/kg | Part 1: Dose-Escalation, 12 mg/kg | Part 1: Dose-Escalation 18 mg/kg | Part 1: Dose-Escalation 24 mg/kg | Part 2: Dose-Expansion, Basket Cohort | Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort | Part 2: Dose-Expansion, NSCLC METex14del Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| 18-65 years | 2 | 1 | 2 | 1 | 20 | 2 | 6 | 34 |
| 65 to <75 years | 1 | 2 | 1 | 2 | 4 | 5 | 0 | 15 |
| 75 to <85 years | 0 | 0 | 0 | 0 | 1 | 1 | 6 | 8 |
| 85 years or older | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part 1: Dose-Escalation, 6 mg/kg | Part 1: Dose-Escalation, 12 mg/kg | Part 1: Dose-Escalation 18 mg/kg | Part 1: Dose-Escalation 24 mg/kg | Part 2: Dose-Expansion, Basket Cohort | Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort | Part 2: Dose-Expansion, NSCLC METex14del Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 2 | 2 | 7 | 5 | 6 | 25 |
| Male | 2 | 1 | 1 | 1 | 18 | 3 | 6 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Dose-Escalation, 6 mg/kg | Part 1: Dose-Escalation, 12 mg/kg | Part 1: Dose-Escalation 18 mg/kg | Part 1: Dose-Escalation 24 mg/kg | Part 2: Dose-Expansion, Basket Cohort | Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort | Part 2: Dose-Expansion, NSCLC METex14del Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 4 |
| Not Hispanic or Latino | 3 | 3 | 3 | 1 | 24 | 8 | 11 | 53 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part 1: Dose-Escalation, 6 mg/kg | Part 1: Dose-Escalation, 12 mg/kg | Part 1: Dose-Escalation 18 mg/kg | Part 1: Dose-Escalation 24 mg/kg | Part 2: Dose-Expansion, Basket Cohort | Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort | Part 2: Dose-Expansion, NSCLC METex14del Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 14 | 2 | 1 | 17 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
| White | 2 | 3 | 3 | 2 | 8 | 6 | 11 | 35 |
| More than one race | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| Region of Enrollment(participants) | Part 1: Dose-Escalation, 6 mg/kg | Part 1: Dose-Escalation, 12 mg/kg | Part 1: Dose-Escalation 18 mg/kg | Part 1: Dose-Escalation 24 mg/kg | Part 2: Dose-Expansion, Basket Cohort | Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort | Part 2: Dose-Expansion, NSCLC METex14del Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| South Korea | 0 | 0 | 0 | 0 | 12 | 2 | 0 | 14 |
| United States | 3 | 3 | 3 | 3 | 6 | 3 | 8 | 29 |
| Taiwan | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Denmark | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Spain | 0 | 0 | 0 | 0 | 6 | 2 | 3 | 11 |
| Body weight(kg) | Part 1: Dose-Escalation, 6 mg/kg | Part 1: Dose-Escalation, 12 mg/kg | Part 1: Dose-Escalation 18 mg/kg | Part 1: Dose-Escalation 24 mg/kg | Part 2: Dose-Expansion, Basket Cohort | Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort | Part 2: Dose-Expansion, NSCLC METex14del Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 82.2 ± 17.86 | 62.5 ± 12.03 | 89.0 ± 18.29 | 69.7 ± 8.05 | 67.1 ± 10.73 | 60.3 ± 11.58 | 72.1 ± 15.54 | 69.1 ± 13.86 |
| Body mass index (BMI)(kg per square meter) | Part 1: Dose-Escalation, 6 mg/kg | Part 1: Dose-Escalation, 12 mg/kg | Part 1: Dose-Escalation 18 mg/kg | Part 1: Dose-Escalation 24 mg/kg | Part 2: Dose-Expansion, Basket Cohort | Part 2: Dose-Expansion, NSCLC MET-Amplified Cohort | Part 2: Dose-Expansion, NSCLC METex14del Cohort | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 28.10 ± 1.132 | 23.65 ± 3.978 | 29.84 ± 7.452 | 25.89 ± 5.363 | 23.58 ± 3.776 | 22.15 ± 4.590 | 25.19 ± 4.081 | 24.44 ± 4.405 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2016 to primary completion in Dec 2020, 57 months.
Results were first posted in Jun 2022, 1 year 6 months after primary completion.
Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 57 months is close to that.
Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Symphogen A/S